Published in J Am Coll Cardiol on April 25, 2005
Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol (2011) 3.74
Detection of myocardial damage in patients with sarcoidosis. Circulation (2009) 2.31
Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging (2007) 1.58
Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging (2016) 1.54
Cardiac sarcoidosis. Heart (2006) 1.34
Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson (2012) 1.17
¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging (2011) 1.15
Cardiac magnetic resonance in myocardial disease. Heart (2006) 1.08
Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev (2013) 1.05
Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med (2014) 1.04
Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance. Heart Fail Clin (2009) 0.96
Extrapulmonary manifestations of sarcoidosis. Rheum Dis Clin North Am (2013) 0.95
Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med (2014) 0.91
The emerging clinical role of cardiovascular magnetic resonance imaging. Can J Cardiol (2010) 0.87
Cardiovascular magnetic resonance imaging of myocardial infarction, viability, and cardiomyopathies. Curr Probl Cardiol (2010) 0.87
Use of tissue Doppler imaging to identify and manage systemic diseases. Clin Res Cardiol (2007) 0.87
Management of cardiac sarcoidosis in the United States: a Delphi study. Chest (2011) 0.83
Advances in Cardiovascular MRI for Diagnostics: Applications in Coronary Artery Disease and Cardiomyopathies. Expert Opin Med Diagn (2009) 0.83
Infiltrative Cardiomyopathies. Clin Med Insights Cardiol (2015) 0.83
Myocardial structural alteration and systolic dysfunction in preclinical hypertrophic cardiomyopathy mutation carriers. PLoS One (2012) 0.81
The role of magnetic resonance imaging in hypertrophic cardiomyopathy. Quant Imaging Med Surg (2014) 0.81
Outcomes of patients with definite and suspected isolated cardiac sarcoidosis treated with an implantable cardiac defibrillator. J Interv Card Electrophysiol (2015) 0.81
Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2011) 0.80
Cardiovascular magnetic resonance: applications in daily practice. Cardiol Rev (2011) 0.79
A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res (2016) 0.79
Role of imaging in the detection of reversible cardiomyopathy. J Cardiovasc Ultrasound (2013) 0.79
Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging (2015) 0.79
Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 1: Common phenotypes. World J Cardiol (2012) 0.78
Cardiac Sarcoidosis: Is it More Common in Men? Lung (2015) 0.77
Diagnostic value of strain echocardiography, galectin-3, and tenascin-C levels for the identification of patients with pulmonary and cardiac sarcoidosis. Lung (2014) 0.76
Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther (2016) 0.76
Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. PLoS One (2016) 0.75
Cardiac sarcoidosis presenting as constrictive pericarditis. Tex Heart Inst J (2014) 0.75
Cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis: presenting as ventricular tachycardia. Tex Heart Inst J (2011) 0.75
Notice from the editor-in-chief and the ethics subcommittee of CHEST associate editors. Chest (2007) 0.75
Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis. Open Heart (2016) 0.75
The natural history of acute dilated cardiomyopathy. Trans Am Clin Climatol Assoc (2014) 0.75
Magnetic resonance imaging in the evaluation of congestive cardiac failure. Indian J Radiol Imaging (2012) 0.75
Cardiac sarcoidosis: case report, workup, and review of the literature. Cardiol Ther (2013) 0.75
Comprehensive cardiac magnetic resonance imaging. J Invasive Cardiol (2009) 0.75
Magnetic resonance imaging of cardiac sarcoidosis: an evaluation of the cardiac segments and layers that exhibit late gadolinium enhancement. Nagoya J Med Sci (2016) 0.75
Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging (2016) 0.75
Prevalence of cardiac sarcoidosis in white population: a case-control study: Proposal for a novel risk index based on commonly available tests. Medicine (Baltimore) (2016) 0.75
CMR Features in Cardiac Sarcoidosis. Case Rep Radiol (2011) 0.75
An unusual cause of sustained ventricular tachycardia in a 27-year-old man. BMJ Case Rep (2013) 0.75
Assessment of cardiac sarcoidosis with advanced imaging modalities. Biomed Res Int (2014) 0.75
Practical applications of cardiovascular magnetic resonance. Heart Asia (2009) 0.75
Sarcoidosis: yet another masquerader the cardiologist / electrophysiologist has to fight with. Indian Pacing Electrophysiol J (2010) 0.75
Utility of cardiac magnetic resonance in assessing right-sided heart failure in sarcoidosis. BMC Med Imaging (2013) 0.75
Cardiac sarcoidosis or giant cell myocarditis? On treatment improvement of fulminant myocarditis as demonstrated by cardiovascular magnetic resonance imaging. Case Rep Cardiol (2011) 0.75
Role of Cardiac MR Imaging in Cardiomyopathies. J Nucl Med (2015) 0.75
Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner? Curr Cardiol Rev (2016) 0.75
Current clinical applications of cardiovascular magnetic resonance imaging. Cardiovasc J Afr (2014) 0.75
The role of imaging in hypertensive heart disease. Int J Angiol (2014) 0.75
Inactive cardiac sarcoidosis with characteristic findings on cardiac MRI. BMJ Case Rep (2013) 0.75
Reconciling Q waves and late gadolinium enhancement with no angiographic evidence of coronary disease: cardiac sarcoidosis presenting as decompensated heart failure. Cardiovasc J Afr (2010) 0.75
A 34-year-old man with cardiac arrhythmias and lymphadenopathy. Clin Res Cardiol (2010) 0.75
The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update. JACC Cardiovasc Imaging (2017) 0.75
Neurosarcoidosis--a diagnostic pitfall with consequences. Wien Klin Wochenschr (2006) 0.75
Role of Imaging in Evaluating Infiltrative Heart Disease. Curr Treat Options Cardiovasc Med (2017) 0.75
Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagnosis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging (2006) 0.75
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry (2007) 4.44
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
Diagnostic accuracy and clinical utility of noninvasive testing for coronary artery disease. Ann Intern Med (2010) 2.80
Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation (2006) 2.63
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50
Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest (2005) 2.50
Effectiveness of nurse-delivered cardiovascular risk management in primary care: a randomised trial. Br J Gen Pract (2010) 2.42
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and trans-thoracic echocardiography in patients referred for transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 2.30
Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J (2005) 2.28
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol (2011) 2.19
Who is at risk of post-MI depressive symptoms? J Psychosom Res (2005) 2.18
Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet (2012) 2.14
Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: a systematic review and meta-analysis. Eur Radiol (2012) 2.14
Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation (2013) 2.11
Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol (2004) 2.10
Effect of smoke-free legislation on the incidence of sudden circulatory arrest in the Netherlands. Heart (2012) 2.10
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA (2008) 2.09
Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol (2013) 2.08
Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction. Heart (2011) 2.06
Combined anterior and inferior ST-segment elevation Electrocardiographic differentiation between right coronary artery occlusion with predominant right ventricular infarction and distal left anterior descending branch occlusion. J Electrocardiol (2011) 2.04
Efficient quantification of the left ventricular volume using 3-dimensional echocardiography: the minimal number of equiangular long-axis images for accurate quantification of the left ventricular volume. J Am Soc Echocardiogr (2007) 1.93
Relation of levels of serum lipoproteins to depression after acute myocardial infarction. Am J Cardiol (2002) 1.92
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol (2009) 1.87
Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study--TROFI trial. Eur Heart J (2013) 1.87
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84
Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis (2011) 1.84
Depression following myocardial infarction: first-ever versus ongoing and recurrent episodes. Gen Hosp Psychiatry (2005) 1.76
Acute results of transvenous cryoablation of supraventricular tachycardia (atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia). J Cardiovasc Electrophysiol (2002) 1.72
Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol (2005) 1.71
Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J (2005) 1.71
Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace (2008) 1.68
How important is the electrocardiogram in protecting and guiding the athlete? Circulation (2011) 1.68
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys (2009) 1.67
Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J (2008) 1.64
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J (2003) 1.63
Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. J Mol Cell Cardiol (2007) 1.61
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace (2011) 1.61
Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J (2011) 1.60
The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace (2010) 1.59
Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57
Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate. J Cardiovasc Electrophysiol (2004) 1.57
Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J (2008) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Changes in mitral regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2010) 1.54
Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J (2004) 1.54
Calculation of effective VV interval facilitates optimization of AV delay and VV interval in cardiac resynchronization therapy. Heart Rhythm (2006) 1.54
The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest (2005) 1.51
The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol (2011) 1.51
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J (2008) 1.51
Magnetic navigation system used successfully to cross a crushed stent in a bifurcation that failed with conventional wires. Catheter Cardiovasc Interv (2007) 1.50
Short- and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute myocardial infarction complicated by cardiogenic shock. Cardiology (2012) 1.46
Validity of coronary heart diseases and heart failure based on hospital discharge and mortality data in the Netherlands using the cardiovascular registry Maastricht cohort study. Eur J Epidemiol (2009) 1.45
Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace (2011) 1.45
How to enhance acute outcome of electrical cardioversion by drug therapy: importance of immediate reinitiation of atrial fibrillation. J Cardiovasc Electrophysiol (2002) 1.45
Clinical outcome following Transcatheter Aortic Valve Implantation in patients with impaired left ventricular systolic function. Catheter Cardiovasc Interv (2012) 1.45
Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years. Catheter Cardiovasc Interv (2012) 1.45
NIRS and IVUS for characterization of atherosclerosis in patients undergoing coronary angiography. JACC Cardiovasc Imaging (2011) 1.42
Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J (2007) 1.42
Will future troponin measurement overrule the ECG as the primary diagnostic tool in patients with acute coronary syndrome? J Electrocardiol (2013) 1.42
Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? Heart Rhythm (2005) 1.42
RR-interval irregularity precedes ventricular fibrillation in ST elevation acute myocardial infarction. Heart Rhythm (2009) 1.42
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace (2013) 1.42
Validity and variability in visual assessment of stenosis severity in phantom bifurcation lesions: a survey in experts during the fifth meeting of the European Bifurcation Club. Catheter Cardiovasc Interv (2011) 1.42
Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol (2007) 1.42
Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. EuroIntervention (2015) 1.40
Atrial natriuretic peptides during experimental atrial tachycardia: role of developing tachycardiomyopathy. J Cardiovasc Electrophysiol (2004) 1.40
Evaluation of the electrocardiogram in identifying and quantifying lateral involvement in nonanterior wall infarction using cardiovascular magnetic resonance imaging. J Electrocardiol (2012) 1.39
MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res (2004) 1.39
Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J (2004) 1.36